The Enterprise Value as of November 2024 (TTM) for GH Research PLC (GHRS) is 332.46M

According to GH Research PLC’s latest financial reports and current stock price. The company's current Enterprise Value is 332.46M. This represents a change of -21.12% compared to the average of 421.45M of the last 4 quarters.

GH Research PLC (GHRS) Historical Enterprise Value (quarterly & annually)

How has GHRS Enterprise Value performed in the past?

The mean historical Enterprise Value of GH Research PLC over the last ten years is 837.76M. The current 332.46M Enterprise Value has changed 3.87% with respect to the historical average. Over the past ten years (40 quarters), GHRS's Enterprise Value was at its highest in in the December 2021 quarter at 936.31M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

GH Research PLC (GHRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of GH Research PLC Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

GH Research PLC (GHRS) Average Enterprise Value

How has GHRS Enterprise Value performed in the past?

The current Enterprise Value of GH Research PLC (GHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

GH Research PLC (GHRS) Enterprise Value vs. Peers

How is GHRS’s Enterprise Value compared to its peers?

GH Research PLC’s Enterprise Value is greater than Molecular Partners AG (57.06M), greater than MediciNova, Inc. (38.55M), greater than Anebulo Pharmaceuticals, Inc. (45.92M), greater than Champions Oncology, Inc. (61.85M), greater than Cyteir Therapeutics, Inc. (-20511738.00), less than Mineralys Therapeutics, Inc. (603.45M), greater than Eliem Therapeutics, Inc. (119.64M), less than Janux Therapeutics, Inc. (2.93B), greater than Rezolute, Inc. (238.32M), greater than PMV Pharmaceuticals, Inc. (48.39M), less than Pharvaris N.V. (857.43M), greater than PepGen Inc. (171.03M), less than Monte Rosa Therapeutics, Inc. (480.50M), greater than Design Therapeutics, Inc. (257.66M), greater than Werewolf Therapeutics, Inc. (2.33M), greater than Ikena Oncology, Inc. (47.35M), less than Stoke Therapeutics, Inc. (494.86M), less than Arcus Biosciences, Inc. (1.28B), less than Cullinan Oncology, Inc. (813.60M), less than Annexon, Inc. (644.17M), less than Structure Therapeutics Inc. (1.92B), less than Relay Therapeutics, Inc. (876.31M),

Build a custom stock screener for GH Research PLC (GHRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GH Research PLC using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

GH Research PLC (GHRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like GH Research PLC or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.